首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Computational analysis of BACE1-ligand complex crystal structures and linear discriminant analysis for identification of BACE1 inhibitors with anti P-glycoprotein binding property
【24h】

Computational analysis of BACE1-ligand complex crystal structures and linear discriminant analysis for identification of BACE1 inhibitors with anti P-glycoprotein binding property

机译:抗P-糖蛋白结合性能鉴定BACE1-配体复合物晶体结构和线性判别分析的计算分析

获取原文
获取原文并翻译 | 示例
           

摘要

More than 100 years of research on Alzheimer’s disease didn’t yield a potential cure for this dreadful disease. Poor Blood Brain Barrier (BBB) permeability and P-glycoprotein binding of BACE1 inhibitors are the major causes for the failure of these molecules during clinical trials. The design of BACE1 inhibitors with a balance of sufficient affinity to the binding site and little or no interaction with P-glycoproteins is indispensable. Identification and understanding of protein–ligand interactions are essential for ligand optimization process. Structure-based drug design (SBDD) efforts led to a steady accumulation of BACE1-ligand crystal complexes in the PDB. This study focuses on analyses of 153 BACE1-ligand complexes for the direct contacts (hydrogen bonds and weak interactions) observed between protein and ligand and indirect contacts (water-mediated hydrogen bonds), observed in BACE1-ligand complex crystal structures. Intraligand hydrogen bonds were analyzed, with focus on ligand P-glycoprotein efflux. The interactions are dissected specific to subsites in the active site and discussed. The observed protein-ligand and intraligand interactions were used to develop the linear discriminant model for the identification of BACE1 inhibitors with less or no P-glycoprotein binding property. Excellent statistical results and model’s ability to correctly predict a new data-set with an accuracy of 92% is achieved. The results are retrospectively analyzed to give input for the design of potential BACE1 inhibitors.
机译:超过100年的阿尔茨海默病的研究并没有对这种可怕的疾病产生潜在的治愈方法。血型脑屏障(BBB)渗透性和脂蛋白结合Bace1抑制剂是临床试验期间这些分子失效的主要原因。 Bace1抑制剂的设计具有足够亲和力的平衡和与对糖蛋白的少量或没有相互作用是必不可少的。对蛋白质 - 配体相互作用的鉴定和理解对于配体优化过程至关重要。基于结构的药物设计(SBDD)努力导致PDB中的Bace1-配体晶体复合物的稳定积累。该研究侧重于在Bace1-配体复合物晶体结构中观察到的蛋白质和配体和间接触点(水介导的氢键)的直接触点(氢键和弱相互作用)的153bace1-配体复合物的分析。分析intraligand氢键,重点在配体p-糖蛋白排出中。将相互作用分解为活性位点中的底座,并讨论。使用观察到的蛋白质 - 配体和脑内相互作用来制定用于鉴定Bace1抑制剂的线性判别模型,较少或没有p-糖蛋白结合性。实现了优异的统计结果和模型的正确预测具有92%的新数据集的能力。回顾性分析结果以给出潜在的Bace1抑制剂的设计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号